{"id":1806,"date":"2020-02-18T14:26:21","date_gmt":"2020-02-18T05:26:21","guid":{"rendered":"https:\/\/clarivate.com\/jp\/blog\/%e5%b8%8c%e5%b0%91%e8%82%89%e8%85%ab%e3%81%aefirst-in-class%e6%b2%bb%e7%99%82%e8%96%actazverik%e3%80%81%e3%81%9d%e3%81%ae%e5%b9%85%e5%ba%83%e3%81%84%e7%94%a8%e9%80%94%e3%81%8c%e5%b8%82%e5%a0%b4\/?lang=ja"},"modified":"2020-02-18T14:26:21","modified_gmt":"2020-02-18T05:26:21","slug":"first-in-class-tazverik-launched-for-rare-sarcoma-wider-use-will-drive-market-value-2","status":"publish","type":"post","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/ja\/blog\/first-in-class-tazverik-launched-for-rare-sarcoma-wider-use-will-drive-market-value-2\/","title":{"rendered":"\u5e0c\u5c11\u8089\u816b\u306eFirst-in-Class\u6cbb\u7642\u85acTazverik\u3001\u305d\u306e\u5e45\u5e83\u3044\u7528\u9014\u304c\u5e02\u5834\u4fa1\u5024\u3092\u9ad8\u3081\u308b"},"content":{"rendered":"

Sabine Puzzovio<\/strong>
\nCortellis\u30a8\u30c7\u30a3\u30bf\u30fc<\/p>\n

 
\n <\/p>\n

\u82f1\u8a9e\u539f\u6587<\/a><\/p>\n

 <\/p>\n

Epizyme\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30fb\u30a4\u30f3\u30fb\u30af\u30e9\u30b9\u6cbb\u7642\u85ac\u3067\u3042\u308bEZH2\uff08zeste\u30db\u30e2\u30ed\u30b02\u30a8\u30f3\u30cf\u30f3\u30b5\u30fc\uff09\u963b\u5bb3\u5264Tazverik\uff08tazemetostat\uff09\u306f\u3001\u91cd\u5927\u306a\u30a2\u30f3\u30e1\u30c3\u30c8\u30cb\u30fc\u30ba\u3067\u3042\u3063\u305f\u8edf\u90e8\u7d44\u7e54\u816b\u760d\u306e\u985e\u4e0a\u76ae\u8089\u816b\uff08ES\uff09\u306e\u6700\u521d\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u7c73\u56fd\u3067\u4f7f\u7528\u53ef\u80fd\u306b\u306a\u308a\u307e\u3057\u305f1,2,3<\/sup>\u3002\u3053\u306e\u85ac\u5264\u306f\u30012020\u5e741\u6708\u306b\u300116\u6b73\u4ee5\u4e0a\u3067\u5b8c\u5168\u5207\u9664\u4e0d\u9069\u306a\u8ee2\u79fb\u6027\u307e\u305f\u306f\u5c40\u6240\u9032\u884c\u6027\u75be\u60a3\u306e\u60a3\u8005\u306b\u5bfe\u3059\u308b\u8fc5\u901f\u627f\u8a8d\u304c\u8a8d\u3081\u3089\u308c\u307e\u3057\u305f3<\/sup>\u3002 Epizyme\u306e\u63a8\u5b9a\u306b\u3088\u308c\u3070\u7c73\u56fd\u306b\u306f\u7d04800\u540d\u306eES\u60a3\u8005\u304c\u304a\u308a\u3001\u305d\u306e\u3046\u3061\u7d04300\u540d\u304cTazverik\u306e\u4f7f\u7528\u306b\u9069\u683c\u3067\u3042\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u30594<\/sup>\u3002 ES\u3067\u306e\u627f\u8a8d\u306f\u91cd\u8981\u306a\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u3067\u3059\u304c\u3001Tazverik\u306f\u6f5c\u5728\u7684\u306b\u3088\u308a\u53ce\u76ca\u6027\u306e\u9ad8\u3044\u304c\u3093\u9818\u57df\u3067\u306e\u4f7f\u7528\u3092\u901a\u3058\u3066\u3001\u305d\u306e\u5e02\u5834\u4fa1\u5024\u304c\u5b8c\u5168\u306a\u3082\u306e\u3068\u306a\u308b\u3053\u3068\u304c\u671f\u5f85\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n

 <\/p>\n

ES\u306b\u5bfe\u3059\u308b\u7d99\u7d9a\u7684\u306a\u6709\u52b9\u6027<\/h3>\n

Tazverik\u306e\u8fc5\u901f\u627f\u8a8d\u306f\u3001\u9032\u884c\u4e2d\u306eEZH-202\uff08NCT02601950\uff09\u30d5\u30a7\u30fc\u30ba2\u8a66\u9a13\u304b\u3089\u306e\u8ee2\u79fb\u6027\u307e\u305f\u306f\u5c40\u6240\u9032\u884cES\u60a3\u800562\u540d\u306e\u81e8\u5e8a\u30c7\u30fc\u30bf\u306b\u57fa\u3065\u3044\u3066\u3044\u307e\u30595,6<\/sup>\u3002\u594f\u529f\u7387\u306f15\uff05\u3067\u3059\u304c\u3001\u305d\u306e\u3046\u306167\uff05\u306e\u594f\u529f\u671f\u9593\u306f6\u304b\u6708\u4ee5\u4e0a\u3067\u3057\u305f6<\/sup>\u3002\u3053\u308c\u3089\u306e\u30c7\u30fc\u30bf\u306f\u3001\u8edf\u90e8\u7d44\u7e54\u8089\u816b\u306e\u6a19\u6e96\u6cbb\u7642\u3067\u3042\u308b\u653e\u5c04\u7dda\u7642\u6cd5\u3084\u3001\u7528\u91cf\u5236\u9650\u6bd2\u6027\u304c\u3042\u308a\u594f\u529f\u738712\u301c23\uff05\u3001\u594f\u529f\u671f\u9593\u306e\u4e2d\u592e\u5024\u304c\u308f\u305a\u304b4.5\u30ab\u6708\u3067\u3042\u308b\u5316\u5b66\u7642\u6cd5\u3068\u6bd4\u8f03\u3057\u3066\u3082\u826f\u597d\u3067\u3057\u305f7,8,9<\/sup>\u3002<\/p>\n

Epizyme\u306f\u73fe\u5728\u3001ES\u306e\u30d5\u30ed\u30f3\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u3068\u3057\u3066Tazverik\u3068\u30c9\u30ad\u30bd\u30eb\u30d3\u30b7\u30f3\u306e\u4f75\u7528\u3092\u8a55\u4fa1\u3059\u308bEZH-301\uff08NCT04204941\uff09\u30d5\u30a7\u30fc\u30ba3\u78ba\u8a8d\u8a66\u9a13\u3092\u5b9f\u65bd\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u8a66\u9a13\u304b\u3089\u5f97\u3089\u308c\u305f\u80af\u5b9a\u7684\u306a\u30c7\u30fc\u30bf\u306f\u3001\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u3067\u306e\u8ffd\u52a0\u627f\u8a8d\u306e\u57fa\u790e\u3068\u306a\u308a\u3001\u6f5c\u5728\u7684\u306aTazverik\u306eES\u5e02\u5834\u3092\u62e1\u5927\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u305910<\/sup>\u3002<\/p>\n

 <\/p>\n

\u4e8c\u6b21\u304c\u3093\u306e\u30ea\u30b9\u30af<\/h3>\n

Tazverik\u306e\u6297\u304c\u3093\u4f5c\u7528\u304c\u30ea\u30b9\u30af\u3068\u306a\u308b\u5834\u5408\u3082\u3042\u308a\u307e\u3059\u3002EZH-102\uff08NCT02601937\uff09\u30d5\u30a7\u30fc\u30baI\u5c0f\u5150\u8a66\u9a13\u3067\u7d9a\u767a\u6027T\u7d30\u80de\u30ea\u30f3\u30d1\u816b\u3092\u767a\u75c7\u3057\u305f\u60a3\u8005\u306e\u5831\u544a\u3092\u53d7\u3051\u3001FDA\u306f2018\u5e744\u6708\u306b\u958b\u767a\u306b\u304a\u3051\u308b\u81e8\u5e8a\u8a66\u9a13\u3092\u4e00\u6642\u4fdd\u7559\u3068\u3057\u307e\u3057\u305f11,12<\/sup>\u3002 \u305d\u306e\u5f8c\u3001FDA\u306f2018\u5e749\u6708\u306b\u3053\u306e\u4e00\u6642\u4fdd\u7559\u3092\u89e3\u9664\u3057\u307e\u3057\u305f\u304c\u3001\u4e8c\u6b21\u304c\u3093\u306b\u95a2\u3059\u308b\u5b89\u5168\u6027\u30b7\u30b0\u30ca\u30eb\u304c\u8a8d\u3081\u3089\u308c\u307e\u3057\u305f13,14<\/sup>\u3002\u81e8\u5e8a\u30d7\u30ed\u30b0\u30e9\u30e0\u3067Tazverik\u3092\u6295\u4e0e\u3055\u308c\u305f668\u540d\u306e\u60a3\u8005\u306e\u3046\u3061\u30010.6\uff05\u304c\u9aa8\u9ac4\u7570\u5f62\u6210\u75c7\u5019\u7fa4\u307e\u305f\u306f\u6025\u6027\u9aa8\u9ac4\u6027\u767d\u8840\u75c5\u3092\u767a\u75c7\u3057\u307e\u3057\u305f\u3002Tazverik\u306e\u6dfb\u4ed8\u6587\u66f8\u306b\u306f\u3001\u4e8c\u6b21\u304c\u3093\u306e\u767a\u75c7\u30ea\u30b9\u30af\u5897\u52a0\u306b\u95a2\u3059\u308b\u8b66\u544a\u304c\u542b\u307e\u308c\u3066\u3044\u307e\u305914<\/sup>\u3002<\/p>\n

 <\/p>\n

Tazverik\u306e\u8f1d\u304f\u30c1\u30e3\u30f3\u30b9<\/h3>\n

ES\u306e\u60a3\u8005\u30d7\u30fc\u30eb\u306f\u5c0f\u3055\u3044\u3067\u3059\u304c\u3001\u3088\u308a\u53ce\u76ca\u6027\u306e\u9ad8\u3044\u4ed6\u306e\u304c\u3093\u7a2e\u3078\u5e02\u5834\u62e1\u5927\u3067\u304d\u308b\u5927\u304d\u306a\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u30022019\u5e7412\u6708\u3001Epizyme\u306f\u518d\u767a\u307e\u305f\u306f\u96e3\u6cbb\u6027\u306e\u6ffe\u80de\u6027\u30ea\u30f3\u30d1\u816b\uff08FL\uff09\u60a3\u8005\u306e\u30b5\u30fc\u30c9\u30e9\u30a4\u30f3\u6cbb\u7642\u85ac\u3068\u3057\u3066NDA\u3092\u63d0\u51fa\u3057\u307e\u3057\u305f15<\/sup>\u3002 FL\u306f30\u7a2e\u985e\u306e\u975e\u30db\u30b8\u30ad\u30f3\u30ea\u30f3\u30d1\u816b\uff08NHL\uff09\u306e1\u3064\u3067\u3042\u308a\u3001NHL\u75c7\u4f8b\u306e20\u301c30\uff05\u3092\u5360\u3081\u3066\u3044\u307e\u305916,17<\/sup>\u3002\u63a8\u5b9a\u306b\u3088\u308b\u3068\u3001\u5168\u4e16\u754c\u3067\u306eNHL\u5e02\u5834\u306f2025\u5e74\u307e\u3067\u306b108\u5104\u30c9\u30eb\u306b\u9054\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u305918<\/sup>\u3002Epizyme\u306f\u3001\u540c\u5264\u3092\u4ed6\u306e\u56fa\u5f62\u304c\u3093\u304a\u3088\u3073\u60aa\u6027\u8840\u6db2\u304c\u3093\u306b\u5bfe\u3057\u3001\u518d\u767a\u304a\u3088\u3073\u30d5\u30ed\u30f3\u30c8\u30e9\u30a4\u30f3\u75be\u75c5\u306b\u304a\u3051\u308b\u5358\u5264\u7642\u6cd5\u306a\u3089\u3073\u306b\u4f75\u7528\u7642\u6cd5\u3068\u3057\u3066\u958b\u767a\u3059\u308b\u3053\u3068\u3082\u8a08\u753b\u3057\u3066\u3044\u307e\u305915<\/sup>\u3002<\/p>\n

 <\/p>\n

\u85ac\u4fa1\u306f\u5e02\u5834\u62e1\u5927\u306e\u53ef\u80fd\u6027\u3092\u53cd\u6620\u3057\u3066\u3044\u307e\u3059<\/h3>\n

\u5927\u898f\u6a21\u5e02\u5834\u306b\u304a\u3051\u308b\u4f7f\u7528\u898b\u901a\u3057\u306f\u3001Epizyme\u306eTazverik\u85ac\u4fa1\u6226\u7565\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u3066\u3044\u307e\u3059\u3002\u540c\u793e\u306f\u3053\u306e\u85ac\u5264\u306e\u4fa1\u683c\u30921\u30f6\u6708\u5206\u5f53\u305f\u308a15,500\u30c9\u30eb\u306b\u8a2d\u5b9a\u3057\u307e\u3057\u305f4,19<\/sup>\u3002\u3057\u304b\u3057\u3001ES\u306e\u9ad8\u3044\u5e0c\u5c11\u6027\u3092\u8003\u616e\u3059\u308b\u3068\u3001Tazverik\u306e\u85ac\u4fa1\u306f\u3001NTRK\u907a\u4f1d\u5b50\u878d\u5408\u3092\u6301\u3064\u56fa\u5f62\u304c\u3093\u306b\u5bfe\u3059\u308b\u30d0\u30a4\u30a8\u30eb\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30fb\u30a4\u30f3\u30fb\u30af\u30e9\u30b9\u306e\u30aa\u30fc\u30d5\u30a1\u30f3\u30c9\u30e9\u30c3\u30b0\u3067\u3042\u308bVitrakvi\u306e\u6708\u984d\u8cbb\u752832,800\u30c9\u30eb\u306b\u6bd4\u3079\u3066\u63a7\u3048\u3081\u3068\u306a\u3063\u3066\u3044\u307e\u305920<\/sup>\u3002Epizyme\u306fTazverik\u3092\u4ed6\u306e\u304c\u3093\u7a2e\u306b\u5bfe\u3059\u308b\u4f7f\u7528\u306b\u95a2\u3057\u3066\u30de\u30fc\u30b1\u30c3\u30c8\u3067\u6709\u5229\u306b\u306a\u308b\u3088\u3046\u9577\u5e74\u306b\u308f\u305f\u308a\u6d3b\u52d5\u3092\u7d9a\u3051\u3066\u3044\u307e\u3059\u3002<\/p>\n

 <\/p>\n

Constellation Pharmaceuticals\u306eCPI-1205\u304a\u3088\u3073CPI-0209\u3001Pfizer\u306ePF-06821497\u306a\u3069\u3001\u3044\u304f\u3064\u304b\u306eEZH2\u963b\u5bb3\u5264\u304c\u69d8\u3005\u306a\u304c\u3093\u7a2e\u306e\u6cbb\u7642\u306e\u305f\u3081\u306b\u958b\u767a\u3055\u308c\u3066\u3044\u307e\u3059\u304c\u3001\u958b\u767a\u306f\u307e\u3060\u521d\u671f\u6bb5\u968e\u3067\u3042\u308a\u3001\u898f\u5236\u5f53\u5c40\u306e\u627f\u8a8d\u306f2023 \u5e74\u307e\u3067\u4e88\u5b9a\u3055\u308c\u3066\u3044\u307e\u305b\u309322,23<\/sup>\u3002\u3057\u305f\u304c\u3063\u3066\u3001Tazverik\u306f\u3001EZH2\u963b\u5bb3\u5264\u306e\u5206\u91ce\u306b\u304a\u3044\u3066\u7af6\u5408\u3088\u308a\u3082\u5148\u306b\u5e02\u5834\u3067\u306e\u5730\u4f4d\u3092\u78ba\u7acb\u3067\u304d\u308b\u30c1\u30e3\u30f3\u30b9\u304c\u3042\u308a\u307e\u3059\u3002\u529b\u5f37\u3044\u58f2\u4e0a\u6210\u9577\u304c\u898b\u8fbc\u307e\u308c\u3001\u627f\u8a8d\u5f8c\u306e\u521d\u5e74\u5ea6\u306b\u3042\u305f\u308b2021\u5e74\u306e\u4e88\u6e2c\u58f2\u4e0a\u9ad8\u306f1\u5104300\u4e07\u30c9\u30eb\u30012024\u5e74\u306b\u306f6\u51041,700\u4e07\u30c9\u30eb\u307e\u3067\u6210\u9577\u3059\u308b\u898b\u8fbc\u307f\u3067\u3059\u3002<\/p>\n

 <\/p>\n

Cortellis Competitive Intelligence<\/a>\u3092\u4f7f\u7528\u3057\u3066\u3001\u958b\u767a\u74b0\u5883\u3092\u7406\u89e3\u3059\u308b\u305f\u3081\u306b\u5fc5\u8981\u306a\u30a4\u30f3\u30c6\u30ea\u30b8\u30a7\u30f3\u30b9\u3092\u53d6\u5f97\u3059\u308b\u65b9\u6cd5\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n

 <\/p>\n

\u53c2\u8003\u6587\u732e<\/strong><\/p>\n

    \n
  1. https:\/\/insights.ovid.com\/pubmed?pmid=3392084<\/a><\/li>\n
  2. https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/1097-0142(197011)26:5%3C1029::AID-CNCR2820260510%3E3.0.CO%3B2-R<\/a><\/li>\n
  3. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-option-specifically-patients-epithelioid-sarcoma-rare-soft-tissue<\/a><\/li>\n
  4. https:\/\/epizyme.gcs-web.com\/events\/event-details\/epizyme-inc-conference-call-1<\/a><\/li>\n
  5. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02601950<\/a><\/li>\n
  6. https:\/\/www.businesswire.com\/news\/home\/20200123005858\/en\/Epizyme-Announces-U.S.-FDA-Accelerated-Approval-TAZVERIK%E2%84%A2<\/a><\/li>\n
  7. https:\/\/pubmed.ncbi.nlm.nih.gov\/25312684-a-phase-1b2-study-of-aldoxorubicin-in-patients-with-soft-tissue-sarcoma\/<\/a><\/li>\n
  8. https:\/\/www.americanjournalofsurgery.com\/article\/S0002-9610(08)00163-3\/fulltext<\/a><\/li>\n
  9. https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/0891060310002249<\/a><\/li>\n
  10. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04204941<\/a><\/li>\n
  11. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02601937<\/a><\/li>\n
  12. https:\/\/www.globenewswire.com\/news-release\/2018\/04\/23\/1485765\/0\/en\/Epizyme-Provides-Update-Regarding-Tazemetostat-Clinical-Program.html<\/a><\/li>\n
  13. https:\/\/epizyme.gcs-web.com\/news-releases\/news-release-details\/epizyme-announces-us-food-and-drug-administration-lifts-partial<\/a><\/li>\n
  14. http:\/\/www.epizyme.com\/wp-content\/uploads\/2020\/01\/TAZVERIK-Prescribing-Information.pdf<\/a><\/li>\n
  15. https:\/\/epizyme.gcs-web.com\/news-releases\/news-release-details\/epizyme-submits-new-drug-application-us-fda-tazemetostat-0<\/a><\/li>\n
  16. https:\/\/www.cancercenter.com\/cancer-types\/non-hodgkin-lymphoma\/types<\/a><\/li>\n
  17. https:\/\/lymphoma.org\/aboutlymphoma\/nhl\/fl\/<\/a><\/li>\n
  18. https:\/\/seekingalpha.com\/article\/4319298-epizyme-one-fda-approval-down-one-to-go-in-coming-months<\/a><\/li>\n
  19. https:\/\/www.cortellis.com\/intelligence\/report\/ci\/eventTranscripts\/13004581<\/a><\/li>\n
  20. https:\/\/www.reuters.com\/article\/us-roche-hldg-fda-pricing\/roche-cancer-treatment-priced-at-17050-a-month-lower-than-rival-vitrakvi-idUSKCN1V61G8<\/a><\/li>\n
  21. https:\/\/www.constellationpharma.com\/constellation-pharmaceuticals-initiates-clinical-development-of-cpi-1205-a-novel-inhibitor-of-ezh2-in-patients-with-lymphoma\/<\/a><\/li>\n
  22. https:\/\/www.globenewswire.com\/news-release\/2019\/09\/24\/1919787\/0\/en\/Constellation-Pharmaceuticals-Advances-CPI-0209-into-Clinical-Trials-Expanding-its-EZH2-Franchise.html<\/a><\/li>\n
  23. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03460977<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Sabine Puzzovio Cortellis\u30a8\u30c7\u30a3\u30bf\u30fc     \u82f1\u8a9e\u539f\u6587   Epizyme\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30fb\u30a4\u30f3\u30fb\u30af\u30e9\u30b9\u6cbb\u7642\u85ac\u3067\u3042\u308bEZH2\uff08zeste\u30db\u30e2\u30ed\u30b02\u30a8\u30f3\u30cf\u30f3\u30b5\u30fc\uff09\u963b\u5bb3\u5264Tazverik\uff08tazemetostat\uff09\u306f\u3001\u91cd\u5927\u306a\u30a2\u30f3\u30e1\u30c3\u30c8\u30cb\u30fc\u30ba\u3067\u3042\u3063\u305f\u8edf\u90e8\u7d44\u7e54\u816b\u760d\u306e\u985e\u4e0a\u76ae\u8089\u816b\uff08ES\uff09\u306e\u6700\u521d\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u7c73\u56fd\u3067\u4f7f\u7528\u53ef\u80fd\u306b\u306a\u308a\u307e\u3057\u305f1,2,3\u3002\u3053\u306e\u85ac\u5264\u306f\u30012020\u5e741\u6708\u306b\u300116\u6b73\u4ee5\u4e0a\u3067\u5b8c\u5168\u5207\u9664\u4e0d\u9069\u306a\u8ee2\u79fb\u6027\u307e\u305f\u306f\u5c40\u6240\u9032\u884c\u6027\u75be\u60a3\u306e\u60a3\u8005\u306b\u5bfe\u3059\u308b\u8fc5\u901f\u627f\u8a8d\u304c\u8a8d\u3081\u3089\u308c\u307e\u3057\u305f3\u3002 Epizyme\u306e\u63a8\u5b9a\u306b\u3088\u308c\u3070\u7c73\u56fd\u306b\u306f\u7d04800\u540d\u306eES\u60a3\u8005\u304c\u304a\u308a\u3001\u305d\u306e\u3046\u3061\u7d04300\u540d\u304cTazverik\u306e\u4f7f\u7528\u306b\u9069\u683c\u3067\u3042\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u30594\u3002 ES\u3067\u306e\u627f\u8a8d\u306f\u91cd\u8981\u306a\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u3067\u3059\u304c\u3001Tazverik\u306f\u6f5c\u5728\u7684\u306b\u3088\u308a\u53ce\u76ca\u6027\u306e\u9ad8\u3044\u304c\u3093\u9818\u57df\u3067\u306e\u4f7f\u7528\u3092\u901a\u3058\u3066\u3001\u305d\u306e\u5e02\u5834\u4fa1\u5024\u304c\u5b8c\u5168\u306a\u3082\u306e\u3068\u306a\u308b\u3053\u3068\u304c\u671f\u5f85\u3055\u308c\u3066\u3044\u307e\u3059\u3002   ES\u306b\u5bfe\u3059\u308b\u7d99\u7d9a\u7684\u306a\u6709\u52b9\u6027 Tazverik\u306e\u8fc5\u901f\u627f\u8a8d\u306f\u3001\u9032\u884c\u4e2d\u306eEZH-202\uff08NCT02601950\uff09\u30d5\u30a7\u30fc\u30ba2\u8a66\u9a13\u304b\u3089\u306e\u8ee2\u79fb\u6027\u307e\u305f\u306f\u5c40\u6240\u9032\u884cES\u60a3\u800562\u540d\u306e\u81e8\u5e8a\u30c7\u30fc\u30bf\u306b\u57fa\u3065\u3044\u3066\u3044\u307e\u30595,6\u3002\u594f\u529f\u7387\u306f15\uff05\u3067\u3059\u304c\u3001\u305d\u306e\u3046\u306167\uff05\u306e\u594f\u529f\u671f\u9593\u306f6\u304b\u6708\u4ee5\u4e0a\u3067\u3057\u305f6\u3002\u3053\u308c\u3089\u306e\u30c7\u30fc\u30bf\u306f\u3001\u8edf\u90e8\u7d44\u7e54\u8089\u816b\u306e\u6a19\u6e96\u6cbb\u7642\u3067\u3042\u308b\u653e\u5c04\u7dda\u7642\u6cd5\u3084\u3001\u7528\u91cf\u5236\u9650\u6bd2\u6027\u304c\u3042\u308a\u594f\u529f\u738712\u301c23\uff05\u3001\u594f\u529f\u671f\u9593\u306e\u4e2d\u592e\u5024\u304c\u308f\u305a\u304b4.5\u30ab\u6708\u3067\u3042\u308b\u5316\u5b66\u7642\u6cd5\u3068\u6bd4\u8f03\u3057\u3066\u3082\u826f\u597d\u3067\u3057\u305f7,8,9\u3002 Epizyme\u306f\u73fe\u5728\u3001ES\u306e\u30d5\u30ed\u30f3\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u3068\u3057\u3066Tazverik\u3068\u30c9\u30ad\u30bd\u30eb\u30d3\u30b7\u30f3\u306e\u4f75\u7528\u3092\u8a55\u4fa1\u3059\u308bEZH-301\uff08NCT04204941\uff09\u30d5\u30a7\u30fc\u30ba3\u78ba\u8a8d\u8a66\u9a13\u3092\u5b9f\u65bd\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u8a66\u9a13\u304b\u3089\u5f97\u3089\u308c\u305f\u80af\u5b9a\u7684\u306a\u30c7\u30fc\u30bf\u306f\u3001\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u3067\u306e\u8ffd\u52a0\u627f\u8a8d\u306e\u57fa\u790e\u3068\u306a\u308a\u3001\u6f5c\u5728\u7684\u306aTazverik\u306eES\u5e02\u5834\u3092\u62e1\u5927\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u305910\u3002   \u4e8c\u6b21\u304c\u3093\u306e\u30ea\u30b9\u30af Tazverik\u306e\u6297\u304c\u3093\u4f5c\u7528\u304c\u30ea\u30b9\u30af\u3068\u306a\u308b\u5834\u5408\u3082\u3042\u308a\u307e\u3059\u3002EZH-102\uff08NCT02601937\uff09\u30d5\u30a7\u30fc\u30baI\u5c0f\u5150\u8a66\u9a13\u3067\u7d9a\u767a\u6027T\u7d30\u80de\u30ea\u30f3\u30d1\u816b\u3092\u767a\u75c7\u3057\u305f\u60a3\u8005\u306e\u5831\u544a\u3092\u53d7\u3051\u3001FDA\u306f2018\u5e744\u6708\u306b\u958b\u767a\u306b\u304a\u3051\u308b\u81e8\u5e8a\u8a66\u9a13\u3092\u4e00\u6642\u4fdd\u7559\u3068\u3057\u307e\u3057\u305f11,12\u3002 \u305d\u306e\u5f8c\u3001FDA\u306f2018\u5e749\u6708\u306b\u3053\u306e\u4e00\u6642\u4fdd\u7559\u3092\u89e3\u9664\u3057\u307e\u3057\u305f\u304c\u3001\u4e8c\u6b21\u304c\u3093\u306b\u95a2\u3059\u308b\u5b89\u5168\u6027\u30b7\u30b0\u30ca\u30eb\u304c\u8a8d\u3081\u3089\u308c\u307e\u3057\u305f13,14\u3002\u81e8\u5e8a\u30d7\u30ed\u30b0\u30e9\u30e0\u3067Tazverik\u3092\u6295\u4e0e\u3055\u308c\u305f668\u540d\u306e\u60a3\u8005\u306e\u3046\u3061\u30010.6\uff05\u304c\u9aa8\u9ac4\u7570\u5f62\u6210\u75c7\u5019\u7fa4\u307e\u305f\u306f\u6025\u6027\u9aa8\u9ac4\u6027\u767d\u8840\u75c5\u3092\u767a\u75c7\u3057\u307e\u3057\u305f\u3002Tazverik\u306e\u6dfb\u4ed8\u6587\u66f8\u306b\u306f\u3001\u4e8c\u6b21\u304c\u3093\u306e\u767a\u75c7\u30ea\u30b9\u30af\u5897\u52a0\u306b\u95a2\u3059\u308b\u8b66\u544a\u304c\u542b\u307e\u308c\u3066\u3044\u307e\u305914\u3002   Tazverik\u306e\u8f1d\u304f\u30c1\u30e3\u30f3\u30b9 ES\u306e\u60a3\u8005\u30d7\u30fc\u30eb\u306f\u5c0f\u3055\u3044\u3067\u3059\u304c\u3001\u3088\u308a\u53ce\u76ca\u6027\u306e\u9ad8\u3044\u4ed6\u306e\u304c\u3093\u7a2e\u3078\u5e02\u5834\u62e1\u5927\u3067\u304d\u308b\u5927\u304d\u306a\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u30022019\u5e7412\u6708\u3001Epizyme\u306f\u518d\u767a\u307e\u305f\u306f\u96e3\u6cbb\u6027\u306e\u6ffe\u80de\u6027\u30ea\u30f3\u30d1\u816b\uff08FL\uff09\u60a3\u8005\u306e\u30b5\u30fc\u30c9\u30e9\u30a4\u30f3\u6cbb\u7642\u85ac\u3068\u3057\u3066NDA\u3092\u63d0\u51fa\u3057\u307e\u3057\u305f15\u3002 FL\u306f30\u7a2e\u985e\u306e\u975e\u30db\u30b8\u30ad\u30f3\u30ea\u30f3\u30d1\u816b\uff08NHL\uff09\u306e1\u3064\u3067\u3042\u308a\u3001NHL\u75c7\u4f8b\u306e20\u301c30\uff05\u3092\u5360\u3081\u3066\u3044\u307e\u305916,17\u3002\u63a8\u5b9a\u306b\u3088\u308b\u3068\u3001\u5168\u4e16\u754c\u3067\u306eNHL\u5e02\u5834\u306f2025\u5e74\u307e\u3067\u306b108\u5104\u30c9\u30eb\u306b\u9054\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u305918\u3002Epizyme\u306f\u3001\u540c\u5264\u3092\u4ed6\u306e\u56fa\u5f62\u304c\u3093\u304a\u3088\u3073\u60aa\u6027\u8840\u6db2\u304c\u3093\u306b\u5bfe\u3057\u3001\u518d\u767a\u304a\u3088\u3073\u30d5\u30ed\u30f3\u30c8\u30e9\u30a4\u30f3\u75be\u75c5\u306b\u304a\u3051\u308b\u5358\u5264\u7642\u6cd5\u306a\u3089\u3073\u306b\u4f75\u7528\u7642\u6cd5\u3068\u3057\u3066\u958b\u767a\u3059\u308b\u3053\u3068\u3082\u8a08\u753b\u3057\u3066\u3044\u307e\u305915\u3002   \u85ac\u4fa1\u306f\u5e02\u5834\u62e1\u5927\u306e\u53ef\u80fd\u6027\u3092\u53cd\u6620\u3057\u3066\u3044\u307e\u3059 \u5927\u898f\u6a21\u5e02\u5834\u306b\u304a\u3051\u308b\u4f7f\u7528\u898b\u901a\u3057\u306f\u3001Epizyme\u306eTazverik\u85ac\u4fa1\u6226\u7565\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u3066\u3044\u307e\u3059\u3002\u540c\u793e\u306f\u3053\u306e\u85ac\u5264\u306e\u4fa1\u683c\u30921\u30f6\u6708\u5206\u5f53\u305f\u308a15,500\u30c9\u30eb\u306b\u8a2d\u5b9a\u3057\u307e\u3057\u305f4,19\u3002\u3057\u304b\u3057\u3001ES\u306e\u9ad8\u3044\u5e0c\u5c11\u6027\u3092\u8003\u616e\u3059\u308b\u3068\u3001Tazverik\u306e\u85ac\u4fa1\u306f\u3001NTRK\u907a\u4f1d\u5b50\u878d\u5408\u3092\u6301\u3064\u56fa\u5f62\u304c\u3093\u306b\u5bfe\u3059\u308b\u30d0\u30a4\u30a8\u30eb\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30fb\u30a4\u30f3\u30fb\u30af\u30e9\u30b9\u306e\u30aa\u30fc\u30d5\u30a1\u30f3\u30c9\u30e9\u30c3\u30b0\u3067\u3042\u308bVitrakvi\u306e\u6708\u984d\u8cbb\u752832,800\u30c9\u30eb\u306b\u6bd4\u3079\u3066\u63a7\u3048\u3081\u3068\u306a\u3063\u3066\u3044\u307e\u305920\u3002Epizyme\u306fTazverik\u3092\u4ed6\u306e\u304c\u3093\u7a2e\u306b\u5bfe\u3059\u308b\u4f7f\u7528\u306b\u95a2\u3057\u3066\u30de\u30fc\u30b1\u30c3\u30c8\u3067\u6709\u5229\u306b\u306a\u308b\u3088\u3046\u9577\u5e74\u306b\u308f\u305f\u308a\u6d3b\u52d5\u3092\u7d9a\u3051\u3066\u3044\u307e\u3059\u3002   Constellation Pharmaceuticals\u306eCPI-1205\u304a\u3088\u3073CPI-0209\u3001Pfizer\u306ePF-06821497\u306a\u3069\u3001\u3044\u304f\u3064\u304b\u306eEZH2\u963b\u5bb3\u5264\u304c\u69d8\u3005\u306a\u304c\u3093\u7a2e\u306e\u6cbb\u7642\u306e\u305f\u3081\u306b\u958b\u767a\u3055\u308c\u3066\u3044\u307e\u3059\u304c\u3001\u958b\u767a\u306f\u307e\u3060\u521d\u671f\u6bb5\u968e\u3067\u3042\u308a\u3001\u898f\u5236\u5f53\u5c40\u306e\u627f\u8a8d\u306f2023 \u5e74\u307e\u3067\u4e88\u5b9a\u3055\u308c\u3066\u3044\u307e\u305b\u309322,23\u3002\u3057\u305f\u304c\u3063\u3066\u3001Tazverik\u306f\u3001EZH2\u963b\u5bb3\u5264\u306e\u5206\u91ce\u306b\u304a\u3044\u3066\u7af6\u5408\u3088\u308a\u3082\u5148\u306b\u5e02\u5834\u3067\u306e\u5730\u4f4d\u3092\u78ba\u7acb\u3067\u304d\u308b\u30c1\u30e3\u30f3\u30b9\u304c\u3042\u308a\u307e\u3059\u3002\u529b\u5f37\u3044\u58f2\u4e0a\u6210\u9577\u304c\u898b\u8fbc\u307e\u308c\u3001\u627f\u8a8d\u5f8c\u306e\u521d\u5e74\u5ea6\u306b\u3042\u305f\u308b2021\u5e74\u306e\u4e88\u6e2c\u58f2\u4e0a\u9ad8\u306f1\u5104300\u4e07\u30c9\u30eb\u30012024\u5e74\u306b\u306f6\u51041,700\u4e07\u30c9\u30eb\u307e\u3067\u6210\u9577\u3059\u308b\u898b\u8fbc\u307f\u3067\u3059\u3002  …<\/p>\n","protected":false},"author":61,"featured_media":1807,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_links_to":"","_links_to_type":0,"footnotes":""},"categories":[1071,1073],"tags":[1130,1075],"class_list":["post-1806","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","category-cortellis","tag-cortellis-competitive-intelligence","tag-life-sciences"],"acf":[],"lang":"ja","translations":{"ja":1806},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/1806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/users\/61"}],"replies":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/comments?post=1806"}],"version-history":[{"count":0,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/1806\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media\/1807"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=1806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/categories?post=1806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/tags?post=1806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}